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Abstract
Purpose: Guanylyl cyclase C (GCC) is one of the most frequent tumor markers todetect the circulating tumor cells (CTCs) in peripheral blood of colorectal cancer(CRC) patients. It has been proposed as a new marker for the molecular staging ofCRC. The level of GCC mRNA expression in peripheral blood of CRC patients wasevaluated to explore its probable correlations with the clinicopathological features.
Methods: Relative quantitative expression analysis of GCC mRNA was performedon 80 blood samples (40 patients and 40 normal) using the Real-time RT-PCR.
Results: GCC mRNA expression was detected in 70% of the CRC blood samples.The level of GCC mRNA expression in peripheral blood of patients was significantlyhigher than that in the normal cases (p = 0.031). Moreover, there was a significantcorrelation between the GCC copy number and advanced stages of tumor (p =0.041). Furthermore, we have observed a significant correlation between tumorsizes and GCC copy numbers (p = 0.050). Conclusion: GCC can be a useful markernot only for detection of CTCs in CRC blood samples, but also for the molecularstaging of colorectal cancer.
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1. IntroductionColorectal cancer (CRC) is the fourth common cancer inthe world with almost one million new cases annuallyand mortality rate of almost 50%.1,2 CRC incidence isvaried in different areas in which there is a higherprevalence in Western countries (North America,Northern and Southern Europe) in comparison with theother regions. Although, CRC is more common indeveloped countries, its prevalence is growing indeveloping countries.3 The age-standardized rate (ASR)
of CRC in Iran is 7.5/105 in females and 8.1/105 inmales, ranking the third and fourth common cancers inIran, respectively.4-7 More than 30% of cases havedeveloped metastasis and approximately 20% ofpatients have unresectable tumors. Although, Surgeryhas the highest impact on survival, it only removesefficiently the tumors, which are in the early stages. Rateof tumor relapses ranges from approximately 10% tomore than 60% for the tumors in stages of I and III,
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respectively.8, 9 CRC is poorly diagnosed in the initialstages of tumor and the symptoms usually appear in theadvanced stages of tumorigenesis. The first sign of CRCprogression appears in the lymph nodes, which is animportant criterion for the histopathological staging.The efficiency of different therapeutic modalities afterthe surgery is directly related to the proper tumorstaging.10 Since circulating free tumor cells can causemicro metastasis 11, 12, detection of such cells in thepatients’ blood can be an important way for themetastasis prediction to provide a non-invasive, faster,and accurate diagnostic method in comparison with thehistopathological analysis. Molecular staging of CRCincludes analysis of tumor cells in lymph nodes,peripheral blood, and bone marrow of patients to get thecomplete and accurate information13. Although,Carcino-embryonic antigen (CEA) and carbohydrateantigen19-9 (CA19-9) are currently applied as clinicalmarkers for the diagnosis and screening of CRC2, 14, CEAexpression is reported in a variety of cancers and is notspecific for the CRC patients15-17. One of the mainapproaches to identify and evaluate the presence ofblood CTCs is assessment of tissue-specific biomarkerssuch as Guanylyl cyclase C (GCC) in CRC patients byRT-PCR based methods 18-20. GCC is a receptor for theparacrine intestinal hormones such as guanylyl,uroguanylylin, and heat-stable entrotoxin (ST). It isexpressed specifically in the apical surface of intestinalepithelial cells from duodenum to rectum, and wasintroduced as a special marker for the CRC10, 21. Despiteof GCC expression in CRC tissues and its role in tumormetastasis, it has been shown that GCC protein andmRNA were not found in extra gastrointestinal tissuesand tumor microenvironments22, 21. Moreover, thisreceptor is continuously expressed during and afterneoplastic transformation of normal epithelial cell toCRC cell. Since GCC expression has been identified in allprimary and metastatic colorectal tumors, it may bedeserved as a suitable prognostic and predictive markerto identify the CRC micro metastasis21, 23. Due to the lack
of specific and universal markers for CRC detection24, inthe present study we assessed the diagnostic efficiencyand importance of GCC copy number variation in theperipheral blood samples of Iranian CRC patients using aquantitative real time PCR technique.
2. Methods and Materials
2.1. Study subjectsForty consecutive histologically confirmed CRC patientswere enrolled in the present study who were undergonethe tumor resection between 2009 to 2011 in ImamReza and Omid Hospitals (Mashhad, Iran) andBaqiatallah Hospital (Tehran, Iran). Clinicopathologicalfeatures of tumors were defined according to theAmerican Joint Commission on Cancer (AJCC) criteria25.In addition, forty healthy volunteers who had normalcolonoscopy reports were served as the control cases.Peripheral blood of selected cases was collected beforethe surgery and any chemo-radio therapeutictreatments. All the patients and healthy volunteers wereinformed about the study and approved the consentforms, which were confirmed by the ethic committee ofMashhad University of Medical Sciences.
2.2. RNA extraction and cDNA synthesisThe peripheral mononuclear cells (PBMCs) wereisolated from the 5 ml of whole blood using alymphocyte separation medium (Lymphodex, QuestBiomedical, UK). Total RNA was extracted from the CRCcell line (HT29) and PBMCs using a Trizol reagent(Roche, Applied Sciences, and Indianapolis, IN).Extracted RNA was analyzed by the agarose gelelectrophoresis and its concentration was determined inan absorbance of 260 and 280 nm using aspectrophotometer. cDNA synthesis from the total RNAwas performed using the cDNA synthesis kit and oligo(dT)18 as amplification primer (Fermentas, Vilnius,Lithuania).
Figure 1: Standard curve of the GCC mRNA copy numbers.
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Figure 2: Quantification of GCC mRNA in blood of patients and healthy donors. Copy number is shown in 1 ml of theperipheral blood.
Figure 3: Scatter plot represents descriptive analysis of the GCC quantitative gene expression in CRC patients and controls.
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2.3. Construction of standardsTo prepare the standard curve, the GCC mRNA fragmentwas amplified using the HT29 cDNA and primersequences which are presented in Table.1. PCR productwas purified using the DNA purification kit (Fermentas,USA), and inserted into the pTZR/57 vector (Fermentas,Vilnius, Lithuania). The recombinant vectors wereextracted and linearized with Mava I and diluted serially.The concentration of linearized vector was determinedspectrophotometrically, and the copy numbers werecalculated as described before26, 27. A standard curvewas prepared from 10-fold serial dilutions of linearizedplasmid containing the GCC gene fragment. Sevenstandards (serial dilution) were included in each run ofreal-time PCR. Each reaction was prepared andperformed in duplicate along with triplicates of 10-foldserial dilutions of the plasmid. The GCC mRNA value wascalculated with a reference to the standard curve (Figure1), whose slope was -3.04 indicating high PCRamplification efficiency (98.4%).
2.4. Quantitative reverse transcription-
polymerase chain reactionQuantitative real-time polymerase chain reaction(qRT-PCR) was performed in duplicate reactions basedon SYBR green (absolute quantitative ct) method(Invitrogen, Carlsbad, CA, USA) in Stratagene Mx-3000Preal-time thermo cycler (Stratagene, La Jolla, CA, USA).Each reaction mix was prepared by adding 10 µl SYBRGreen, 0.04 µl ROX, 0.6 µl of each primer (10 pmol/µl), 3µl cDNA, and 5.76 µl DEPC water in a total volume of 20µl. The thermal profile was applied as 10 min of initialdenaturation at 95ºC, followed by 45 cycles at 95ºC for30s, 60ºC for 30s, and 72ºC for 30s. Glyceraldehyde3-phosphate dehydrogenase (GAPDH) was used as theendogenous control to normalize the data 28, 29.
2.5. Statistical analysisThe statistical analysis was performed using the SPSS16.0 (SPSS, Chicago, IL, USA). The associations betweencategorical data (lymph node involvement, tumor size,location, grade, and stage) and GCC copy numbers wereexamined using the Spearman, Mann–Whitney U, andthe Kruskal–Wallis H-tests. A value of p ≤ 0.05 wasconsidered statistically significant.
3. ResultsA total of 40 CRC patients consisting of 30 males and 10females were recruited for the present study. The totalmean age was 59.117.6 years ranging between 25 to 86years. The sex ratio for 40 control cases was 1.4 (23males, 17 females) with mean age of 57.2  7.3 years.Clinicopathological features of the patients aresummarized in Table.2. Most of cases were moderatelydifferentiated (22/40, 55%) and located in distal colon(26/40, 65%). Only 9 out of 40 cases (22.5%) had lymphnode metastasis. Range of tumor sizes were between 1to 10 cm with mean size of (4.90  1.98 cm).  Majorityof cases were in tumor stages of B2 (18/40, 45%) andC2 (11/40, 27.5%). Real-time PCR analysis of thecirculating GCC mRNA revealed that the levels of GCCmRNA in the peripheral blood of the patients wassignificantly higher than that in the controls (70% vs.53%, p = 0.031) (Figures 2 and 3). The mean copynumber of GCC mRNA in peripheral blood of the patientsand normal cases were 2.17E3  5624.20 and 47.15 42.95 copies, respectively. The level of GCC copy numberhad significantly increased in advanced stages of tumor(p = 0.041). This marker produced an overall sensitivityof 70% and a specificity of 46%.  Although there wasnot any significant correlation between the tumor gradeand levels of GCC mRNA expression, moderatelydifferentiated tumors had higher levels of GCCexpression in comparison with the well differentiatedcases (2.52E3  1.29E3 Vs. 1.96  1.37E3, copynumbers). In the case of lymph node status, there wasnot also any significant correlation with the GCC copynumbers. However, as we expected, levels of GCC mRNAexpression in patients with metastatic lymph nodeswere higher than that in the other cases (4.38E3 2.48E3 vs. 1.53E3  8.89E2, copy numbers). Moreover,patients with proximal tumors had shown higher GCCcopy numbers in their peripheral blood in comparisonwith the cases with distal tumors (3.23E3  2.00E3 vs.1.59E3  8.60E2, copy numbers). While, there was asignificant correlation between the GCC copy numbersand tumor sizes (p = 0.050), there was not anysignificant correlation between GCC copy number andage of patients (p = 0.731).
Table 1: Primer Sequences which are used in cloning and qRT-PCR.Primer Sequence (5’ to 3’) Size (bp)GCC(Real timePCR) F:GACCACAACAGGAAAAGCAATCR:AGGCAAGACGAAAGTCTCGTTT 262GCC(Cloning) F:AAACTGAGGACTGGTTCTGGTACCR: GTCACTGGACCGTCATACCCT 510GAPDH F: GGAAGGTGAAGGTCGGAGTCAR:GTCATTGATGGCAACAATATCCACT 101
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Table 2: Clinicopathological features of CRC patients.Total GCC mRNA(mean copy number) P ValuePatients 40 2.17E3±5624.20Mean age (mean ± SD) 59.05±17.61 0.731Size (mean ± SD) 4.90±1.98 0.050Sex 0.390Male 30(75.0%) 2.62E3±1.17E3Female 10(25.0%) 8.25E2±4.25E2Location 0.387Proximal 14(35.0%) 3.23E3±2.00E3Distal 26(65.0%) 1.59E3±8.60E2Grade 0.594P.D 2(5.0%) 13.50±0.00M.D 22(55.0%) 2.52E3±1.29E3W.D 16(40.0%) 1.96E3±1.37E3
4. DiscussionDespite different diagnostic methods, CRC is still one ofthe leading cause of cancer related deaths in the worldand most of cases are detected in advanced stages oftumor leading to an inefficient therapy30. Thereforefinding a specific tumor marker is essential for the earlydetection31. Although, surgery is one of the besttreatment strategies in early stages of CRC, between30-50% of such patients face with the tumor relapse andmetastasis32, 27, 33. Micro metastasis plays a key role intumor relapse in which, the tumor cells spread from theprimary site to the other organs through the lymphaticcirculation or bloodstream34. Molecular staging of CRCusing the specific molecular techniques allows detectionof CTCs which cannot be achieved by the histologicalstaging. Accuracy and fidelity of a tumor staging markeris related to its frequency of expression and preferentialexpression in a specific tumor when compared to theother types of normal or tumor tissues10. Although, CEAis one of the main tumor markers for CRC detection, ithas some limitations such as poor specificity andsensitivity. We have recently reported that Sall4 andCEA can be used as sensitive serum markers for theearly CRC detection and screening26, 27. However, SALL4had higher sensitivity in comparison with the CEA(96.1% vs. 80%). Indeed, introducing more specificmarkers prepares a complete panel of specific markersfor the CRC screening. Therefore, following our recentstudies, in the present study we assessed the levels ofGCC mRNA expression using the quantitative Real-timePCR method in peripheral blood of CRC patients. TheGCC copy numbers were significantly higher inperipheral blood of CRC patients in comparison with thehealthy control group. The results showed that there is asignificant correlation between the high copy numbersof blood GCC mRNA and tumor stage and size. Low levelsof GCC expression has been reported in normalintestinal mucosa cells, while it is over expression has
been identified in colorectal cancer cells and all primaryand metastatic colorectal tumors22, 35, 36, 37. GCC mayimprove the criteria of a suitable prognostic andpredictive marker to identify the colorectal micrometastasis21. It has been demonstrated that GCC overexpression in CRC patients is highly associated withtumor relapse and may enhance the accuracy of staging.GCC is also introduced as the most sensitive and specifictumor marker for detection of metastatic CRC inextra-intestinal tissues21, 37. It can be used as anoninvasive tool for the micro metastasis diagnosis inclinical testing and as an indicator of therapeuticresponse. Therefore, GCC can be used as a suitablemarker for the monitoring of circulating tumor cells inperipheral blood of CRC patients38, 39. Our dataconfirmed the previous studies and suggested copynumber variation of GCC to improve monitoringmethods of prognosis in CRC patients.
5. ConclusionIn conclusion, regarding our recent reports and presentstudy, a panel of multiple specific markers such as Sall4,CEA, and GCC can be a more accurate method incomparison with the single markers for theidentification of CTCs in CRC peripheral bloods.Moreover, there was a significant correlation betweenthe GCC copy numbers and stage of tumors whichintroduced GCC as a selective non-invasive marker notonly for the measuring of free tumor cells in theperipheral blood of CRC patients, but also for themolecular tumor staging.
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